Table 3.
Comparison of AS subjects with respect to disease activity
| Active patients(BASDAI ≥ 4; n= 38) | Inactive patients(BASDAI < 4; n= 17) | pvalue | |
|---|---|---|---|
|
IL-6 (pg/mL) |
20 (6–545) |
15 (5–277) |
0.2 |
|
IFNγ (pg/mL) |
0.002 (0.002–1.96) |
0.002 (0.002–0.89) |
0.7 |
|
BAP (U/L) |
28 (13–107) |
30 (15–49) |
0.3 |
|
Vitamin D (nM) |
89 (4–266) |
77 (12–240) |
0.6 |
|
NTX (nM, bone collagenequivalent) |
87 (56–131) |
81 (52–188) |
0.7 |
|
TRAP 5 (U/L) |
3.7 (2.2–5.8) |
3.9 (2.4–6.6) |
0.4 |
|
hPTH (pg/mL) |
46 (44–170) |
77 (45–130) |
0.08 |
|
sRANKL (pmol/L) |
264 (101–956) |
350 (158–1598) |
0.2 |
|
OPG (pg/mL) |
367 (52–1118) |
274 (71–592) |
0.004 |
|
sRANKL/OPG |
0.79 (0.14–4.5) |
1.16 (0.4–22.6) |
0.02 |
|
Sclerostin (pmol/L) |
70 (49–126) |
75 (48–123) |
0.7 |
|
sFRP1 (ng/mL) |
0.15 (0.1–17) |
0.1 (0.1–0.2) |
0.5 |
|
DKK1 (pg/mL) |
93 (26–370) |
130 (17–771) |
0.5 |
|
BASRI-hip |
0 (0–4) |
0.5 (0–4) |
0.2 |
|
BASRI-spine |
5.5 (2–12) |
7 (2–12) |
0.3 |
|
BASMI |
4 (1–9) |
2.5 (1–9) |
0.7 |
|
BMD-Lumbar spine (g/cm2) |
0.9 (0.7–1.4) |
0.9 (0.7–1.6) |
0.8 |
| BMD-Femoral neck (g/cm2) | 0.7 (0.6–1.1) | 0.8 (0.5–1) | 0.9 |
Data are presented as the median with minimum and maximum values. BASDAI= Bath ankylosing spondylitis disease activity index, IL-6= interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1, BASRI= Bath Ankylosing spondylitis radiologic index, BASMI= Bath ankylosing spondylitis metrology index.